Hepatitis B and End-Stage Liver Disease

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 893-916

  Weisberg, Ilan S ^a   Brown Jr , Robert S ^b   Sigal, Samuel H ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PLACEBO; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GENETIC POLYMORPHISM; HEPATITIS B; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PREVALENCE; REVIEW; RISK FACTOR; SEROCONVERSION; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER FAILURE; MALE;

EID: 35548946090     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.009     Document Type: Review

References (132)

1. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin Liver Dis 25 Suppl 1 (2005) 3-8
2. Perz J.F., Armstrong G.L., Farrington, et al. The contributions of hepatitis B and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006) 529-538
3. Lee W.M. Medical progress: hepatitis B. N Engl J Med 337 (1997) 1733-1745
4. Sherman A., Tsang T., Villanueva G., et al. Mass screening in New York city reveal extraordinarily high prevalence of hepatitis B in an urban Asian population. [Abstract]. Hepatology 42 (2005) 214A
5. Lok A.S.F. Chronic hepatitis B. N Engl J Med 346 (2002) 1682-1683
6. Lo K.J., Tong M.J., Chien M.C., et al. The natural course of hepatitis B surface antigen positive chronic active hepatitis in Taiwan. J Infect Dis 146 (1982) 205-210
7. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
8. Fattovich G., Brollo L., Giustina G., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 32 (1991) 294-298
9. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 23 (2003) 47-58
10. Weissberg J.I., Andres L.L., Smith C.I., et al. Survival in hepatitis B. Ann Intern Med 101 (1984) 613-616
11. Liaw Y.F., Lin D.Y., Chen T.J., et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 9 (1989) 235-241
12. De Jongh F.E., Janssen H.L.A., De Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
13. Realdi G., Fattovich G., Hadziyannis S., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 21 (1994) 656-666
14. Kobayashi M., Ikeda K., Hosaka T., et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 78 (2006) 459-465
15. Chu C.M., and Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26 (2006) 142-152
16. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 21 (1995) 77-82
17. Hui A.Y., Chan L.Y.C., Leung N.W.Y., et al. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 34 (2002) 569-572
18. Chan H.L.Y., Chim A.M.L., Lau J.T.F., et al. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastrotenterol 101 (2006) 1516-1523
19. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
20. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol 130 (2006) 678-686
21. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biologic gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
22. Sumi H., Yokosuka O., Seki N., et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37 (2003) 19-26
23. Chu C.M., and Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43 (2005) 411-417
24. Halfon P., Bourliere M., Pol S., et al. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat 13 (2006) 329-335
25. Kao J.H., Chen P.J., Lai M.Y., et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterol 124 (2003) 327-334
26. Lin C.L., Liao L.Y., Wang C.S., et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 25 (2005) 564-570
27. Tong M.J., Blatt L.M., Kao J.H., et al. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 12 (2006) 6620-6626
28. Song B.C., Kim S.H., Kim H., et al. Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. J Med Virol 76 (2005) 194-202
29. Huo T., Wu J.C., Hwang S.J., et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 12 (2000) 687-693
30. Moreno-Otero R., Garcia-Monzon C., Garcia-Sanchez A., et al. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HbeAg-positive asymptomatic patientws. Am J Gastroenterol 86 (1991) 560-564
31. Chu C.M., Liaw Y.F., Sheen I.S., et al. Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody. Hepatology 3 (1983) 947-950
32. Chu C.M., Sheen I.S., Lin S.M., et al. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis 16 (1993) 709-713
33. Tsai J.F., Chuang L.Y., Jeng J.E., et al. Sex differences in relation to serum hepatitis B e antigen and alanine aminotransferase levels among asymptomatic hepatitis B surface antigen carriers. J Gastroenterol 35 (2000) 690-695
34. Yu M.W., Cheng S.W., Lin M.W., et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 92 (2000) 2023-2028
35. Xiao F., Wei H., Song S., et al. Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 21 (2006) 1488-1491
36. Mah Y.H., Kao J.H., Liu C.J., et al. Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. Liver Int 25 (2005) 214-219
37. Niro G.A., Fontana R., Gioffreda D., et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int 25 (2005) 1175-1181
38. Ohnishi K., Iida S., Iwama S., et al. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 49 (1984) 672-677
39. Chen C.J., Liang K.Y., Chang A.S., et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 13 (1991) 398-406
40. Mason A.L., Lau J.Y., Hoang N., et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29 (1999) 328-333
41. Chen H.F., Li C.Y., Chen P., et al. Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc 69 (2006) 146-152
42. Paptheodoridis G.V., Chrysanthos N., Savvas S., et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 313 (2006) 303-310
43. Huo T.I., Wu J.C., Lee P.C., et al. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol 30 (2000) 250-254
44. Altlparmak E., Koklu S., Yalinkilic M., et al. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol 11 (2005) 3056-3059
45. Thomopoulos K.C., Arvaniti V., Tsamantas A.C., et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 18 (2006) 233-237
46. Gordon A., McLean C.A., Pedersen J.S., et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol 43 (2005) 38-44
47. Chu C.M., Lin D.Y., and Liaw Y.F. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?. Int J Obes 31 (2007) 871-875
48. Hoofnagle J.H., Dusheiko G.M., Seef L.B., et al. Seroconversion from hepatitis B e antigen to antibody in chronic hepatitis type B hepatitis. Ann Intern Med 94 (1981) 744-748
49. Fattovich G., Rugge M., Brollo L., et al. Clinical, virologic and histologic outcome following seroconversion from HbeAg to anti-Hbe in chronic hepatitis B. Hepatology 6 (1986) 167-172
50. Bataller R., and Brenner D.A. Liver fibrosis. Clin Investig 115 (2005) 209-218
51. Pares A., Caballeria J., Bruguera M., et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex, and extent of hepatic damage. J Hepatol 2 (1986) 33-42
52. Mohamadnejad M., Malekzadeh R., Nasseri-Moghaddam S., et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 50 (2005) 547-551
53. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: improvement in liver histologic analysis with weight loss. Hepatology 39 (2004) 1647-1654
54. Arif A., Levine R.A., Sanderson S.O., et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 48 (2003) 1425-1430
55. Inagaki Y., Nemoto T., Kushida M., et al. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38 (2003) 890-899
56. Mathew T.C., Abdeen S., Dashti H., et al. Effect of alpha-interferon and alpha-tocopherol in reversing hepatic cirrhosis in rats. Anat Histol Embryol 36 (2007) 88-93
57. Lau G.K.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HbeAg positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
58. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
59. Lau D.T.Y., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastrotenterology 113 (1997) 1660-1667
60. Fattovich G., Giustina G., Realdi G., et al. Long-term outcome of hepatitis B e antigen positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 26 (1997) 1338-1342
61. Lin S.M., Yu M.L., Lee C.M., et al. Interferon therapy in HbeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
62. Malekzadeh R., Mohamadnejad M., Rakhshani N., et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2 (2004) 344-347
63. Lai C.L., Chien R.N., Leung N.W.Y., et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
64. Suzuki Y., Kumada H., Ikeda K., et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30 (1999) 743-748
65. Dienstag J.L., Schiff E.R., and Wright T.L. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
66. Kweon Y.O., Goodman Z.D., Dienstag J.L., et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 35 (2001) 749-755
67. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
68. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HbeAg -negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1026
69. Lai CL, Gane E, Hsu C, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine [abstract]. Presented at the American Association for the Study of Liver Disease (AASLD), October 30, 2006.
70. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HbeAg negative chronic hepatitis B for up to 5 years. Gastroetenrology 131 (2006) 1743-1751
71. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
72. Kiki I., Yilmaz O., Erdem F., et al. Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh Scores. Int J Clin Pract 9 (2006) 1075-1079
73. Sigal S.H., Ala A., Ivanov K., et al. Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: a possible mechanism to explain the response to antiviral therapy. Liver Transpl 11 (2005) 82-88
74. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
75. Montano-Loza A.J., and Czaja A.J. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 202-214
76. Perrillo R., Tamburro C., Regenstein F., et al. Low dose, titrateable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterol 109 (1995) 908-916
77. Hoofnagle J.H., Di Bisceglie A.M., Waggoner J.G., et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 (1993) 1116-1121
78. Marcellin P., Giuily N., Loriot M.A., et al. Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis. J Viral Hepat 4S (1997) 21-26
79. Villeneuve J.P., Condreay L.D., Willems B., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31 (2000) 207-210
80. Kapoor D., Guptan R.C., Wakil S.M., et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33 (2000) 308-312
81. Hann H.W., Fontana R.J., Wright T., et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 9 (2003) 49-56
82. Yao F.Y., Terrault N.A., Freise C., et al. Lamivudine is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis b infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34 (2001) 411-416
83. Manolakopoulos S., Karatapanis S., Elefsiniotis J., et al. Clinical course of lamivudine monotherapy in patients decompensated cirrhosis due to HbeAg negative chronic HBV infection. Am J Gastroenterol 99 (2004) 57-63
84. Fontana R.J., Hann H.W., Perillo R.P., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
85. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
86. Lacombe K., Gozlan J., Boelle P.Y., et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 19 (2005) 907-915
87. Benhamou Y., Fleury H., Trimoulet, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
88. Taltuvull T.C., Chahri N., Verdura B., et al. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl Int 18 (2005) 879-883
89. Ratziu V., Thibault V., Benhamou Y., et al. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol 5 (2006) 1
90. Keeffe E.B., Dieterich D.T., Han S.H.B., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
91. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
92. Yuen M.F., Chow D.H., Tsui K., et al. Liver histology of Asian patients with chronic hepatitis B on prolonged therapy. Aliment Pharmicol Ther 21 (2005) 841-849
93. Yim H.J., Byun K.S., Chang Y.J., et al. Levels of hepatitis B virus (HBV) replication during the nonreplicative phase: HBV quantification by real-time PCR in Korea. Dig Dis Sci 52 (2007) 2403-2409
94. Chien R.N., Lin C.H., and Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 38 (2003) 322-327
95. Tsubota A., Arase Y., Suzuki Y., et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastrotenterol Hepatol 20 (2005) 426-432
96. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
97. Suzuki Y., Arase Y., Ikeda K., et al. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did or did not develop. Intervirology 46 (2003) 164-170
98. Rizzetto M., Tassopoulos N.C., Goldin R.D., et al. Extended lamivudine treatment in patients with HbeAg-negative chronic hepatitis B. J Hepatol 42 (2005) 173-179
99. Yuen M.F., Yuan H.J., Wong D.K., et al. Prognostic determinants of chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
100. Lim S.G., Wai C.T., Rajnakova A., et al. Fata hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 51 (2002) 597-599
101. Zhang J.M., Wang X.Y., Huang Y.X., et al. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy. J Med Virol 78 (2006) 324-328
102. Honkoop P., de Man R.A., Niesters H.G., et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32 (2000) 635-639
103. Ghany M., and Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroetnerology 132 (2007) 1574-1585
104. Fung S.K., Andreone P., Han S.H., et al. Adefovir resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 (2005) 937-943
105. DiMarco V., DiStefano R., Ferraro D., et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 10 (2005) 431-439
106. Wiegand J., Tischendorf J.J., Nashan B., et al. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Z Gastroenterol 42 (2004) 15-18
107. Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, April 11-15, 2007.
108. Sheldon J., Camino N., Rodes B., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 (2005) 727-734
109. Locarnini S. Molecular virology and the development of resistance mutants: implications for therapy. Semin Liver Dis 25S (2006) 9-19
110. Sung J.J.Y., Lai J.Y., Zeuzem S., et al. A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis. J Hepatol 38 Suppl 2 (2003) 25-26
111. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
112. Liaw Y.F. Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how?. Hepatology 45 (2007) 266-268
113. Kim K.M., Choi W.B., Lim Y.S., et al. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine resistant hepatitis B virus. J Korean Med Sci 20 (2005) 821-828
114. Liaw Y.F., Lee C.M., Chien R.N., et al. Switching to adefovir monotherapy after the emergence of lamivudine resistant mutations in patients with liver cirrhosis. J Viral Hepat 13 (2006) 250-255
115. Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, April 11-15, 2007.
116. Rapti I., Dimou E., Mitsoula P., et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis. Hepatology 45 (2007) 307-313
117. Chang T., Gish R., De Man R., et al. A comparison of entecavir and lamivudine in HbeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
118. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38 (2003) 1419-1427
119. Terrault N., Roche B., and Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 11 (2005) 716-732
120. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
121. Han S.H., Ofman J., Holt C., et al. An efficacy and cost-effectiveness strategy of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 6 (2001) 741-748
122. Kim W.R., Poterucha J.J., Kremers W.K., et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 10 (2004) 968-974
123. Rosenau J., Bahr M., Tillman H.L., et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895-902
124. Seehofer D., Rayes N., Naumann U., et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 72 (2001) 1381-1385
125. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplant using combination lamivudine and hepatitis B immune globulin. Hepatology 28 (1998) 585-589
126. Angus P.W., McCaughan G.W., Gane E.J., et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 6 (2000) 429-433
127. Marzano A., Salizzoni M., Debernardi-Vernon W., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34 (2001) 903-910
128. Gane E.J., Angus P.W., Strasser S., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132 (2007) 931-937
129. Buti M., Mas A., Prieto M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38 (2003) 811-817
130. Wong S.N., Chi-Jen C., Chun-Tao W., et al. Low risk of hepatitis B virus recurrence after treatment withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13 (2007) 374-381
131. Neff G.W., Kemmer N., Kaiser T.E., et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dise Sci 52 (2007) 2497-2500
132. Fontana R.J., Keeffe E.B., Carey W., et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Trasnpl 8 (2002) 433-439